A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.

about

A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.

Item

http://www.wikidata.org/entity/Q51425302

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

A randomized, multi-center, op ...... hemotherapy for breast cancer.

@en

A randomized, multi-center, op ...... hemotherapy for breast cancer.

@nl

type

Item

label

A randomized, multi-center, op ...... hemotherapy for breast cancer.

@en

A randomized, multi-center, op ...... hemotherapy for breast cancer.

@nl

prefLabel

A randomized, multi-center, op ...... hemotherapy for breast cancer.

@en

A randomized, multi-center, op ...... hemotherapy for breast cancer.

@nl

P1476

A randomized, multi-center, op ...... hemotherapy for breast cancer.

@en

P2093

H J Lee

http://www.w3.org/2001/XMLSchema#string

H Y Kim

http://www.w3.org/2001/XMLSchema#string

I H Park

http://www.w3.org/2001/XMLSchema#string

J H Park

http://www.w3.org/2001/XMLSchema#string

Jae Hong Seo

http://www.w3.org/2001/XMLSchema#string

K H Jung

http://www.w3.org/2001/XMLSchema#string

K H Park

http://www.w3.org/2001/XMLSchema#string

S I Lee

http://www.w3.org/2001/XMLSchema#string

S Lee

http://www.w3.org/2001/XMLSchema#string

S Park

http://www.w3.org/2001/XMLSchema#string

P2860

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Pharmacokinetics of pegfilgrastim.

Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy.

A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09

Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.

Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials.

P2888

s00520-016-3429-2

P304

505-511

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00520-016-3429-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27709313

http://www.w3.org/2001/XMLSchema#string